Oral Hypoglycemic Agents (OHAs) Market is expected to undergo a CAGR of 4.00% during the forecast period.
Overview The Oral Hypoglycemic Agents (OHAs) market is poised for consistent growth, driven primarily by the increasing global prevalence of type 2 diabetes mellitus (T2DM). Oral hypoglycemic agents are non-insulin medications used to lower blood sugar levels in individuals suffering from T2DM. They work through different mechanisms such as increasing insulin sensitivity, stimulating insulin production, or slowing down glucose absorption in the intestines. As diabetes becomes a more widespread issue, the demand for effective oral medications is expected to grow, benefiting the OHA market. Market Size and Forecast In 2022, the market for OHAs was valued at approximately USD 61.20 billion , and it is projected to grow to USD 83.75 billion by 2030 , with a compound annual growth rate (CAGR) of 4.00% from 2023 to 2030. This growth is fueled by the increasing number of diabetes cases and advancements in drug formulations that are mo...